C. difficile and Fecal Microbiota Transplant: The Beginnings of Microbiome Therapy

Content Type: presentation

Presenter: Neil H. Stollman, MD, FACG

Presenter Disclosure: Advisory Board: OpenBiome; Consultant: Assembly Biopharma; Research Grant: Assembly Biopharma; Royalties: UpToDate; Speakers Bureau: RedHill Biopharma; Stockholder: Robin Healthcare

Event: ACG Virtual Grand Rounds

Release Date: 5/15/2020

Expiration Date: 5/15/2023

Objective: Advise patients on appropriate treatment regimens for C. difficile infection in uncomplicated and complicated patients, appropriately utilize the newest therapies for C. difficile infection, specifically the current status of Fecal Microbiota Transplant (FMT), and apply recent data regarding the role of FMT in special populations, such as the immunosuppressed and those with IBD.